Corient Private Wealth LP Buys Shares of 108,403 PROCEPT BioRobotics Corporation $PRCT

Corient Private Wealth LP purchased a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 108,403 shares of the company’s stock, valued at approximately $2,448,000.

Several other large investors have also made changes to their positions in the company. Versant Capital Management Inc raised its position in PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after purchasing an additional 1,084 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after purchasing an additional 746 shares during the last quarter. Center for Financial Planning Inc. bought a new position in shares of PROCEPT BioRobotics in the 4th quarter valued at $40,000. Cache Advisors LLC acquired a new position in shares of PROCEPT BioRobotics during the 1st quarter worth $42,000. Finally, Essential Partners LLC raised its holdings in shares of PROCEPT BioRobotics by 7,071.4% during the 1st quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock worth $50,000 after buying an additional 1,980 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

Insider Activity

In other news, CEO Larry L. Wood acquired 23,900 shares of the stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the purchase, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 1,000 shares of company stock valued at $28,480 over the last three months. Corporate insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Trading Up 5.1%

Shares of PRCT stock opened at $21.97 on Thursday. The firm has a market capitalization of $1.26 billion, a P/E ratio of -11.32 and a beta of 0.91. PROCEPT BioRobotics Corporation has a twelve month low of $16.67 and a twelve month high of $41.51. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The stock’s fifty day simple moving average is $20.35 and its 200 day simple moving average is $23.74.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same quarter in the prior year, the business posted ($0.35) earnings per share. PROCEPT BioRobotics’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. UBS Group downgraded shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a research note on Tuesday, July 28th. Piper Sandler decreased their price target on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Evercore set a $23.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $25.09.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Analyst sentiment toward PROCEPT BioRobotics was described as mixed, suggesting investors may remain divided on the company’s outlook. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Negative Sentiment: Several law firms publicized a securities fraud class action against PROCEPT BioRobotics and urged investors who purchased shares between February 28, 2024, and February 25, 2026, to seek lead-plaintiff status by September 22, 2026. The repeated announcements increase visibility around the legal risk and may weigh on investor sentiment. Kaplan Fox Urges Investors of PROCEPT BioRobotics Corporation
• Negative Sentiment: The allegations center on surprise weakness in unit handpiece sales, excess customer inventory, and repeated late-quarter bulk discounts. Plaintiffs claim these practices obscured demand problems, inflated recurring-revenue metrics, and pulled forward sales. The related disclosures were cited as contributing to an approximately 18% stock decline during the alleged class period. PROCEPT BioRobotics Corporation Securities Fraud Class Action
• Negative Sentiment: Additional notices allege that management attributed revenue volatility to temporary saline shortages rather than inventory overstocking. These are allegations, not established findings, but the litigation creates potential financial, reputational, and disclosure-related risks for PRCT. Levi & Korsinsky Reminds Shareholders

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.